[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Geistlich Pharma North America, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":55},{"warningLetters":4,"total":54},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21709,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-pharma-mfg-inc-728227-08042026\">American Pharma Mfg. Inc. \u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vishal D. Savalia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Pharma Mfg. Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1845 S. Vineyard Ave Ste 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ontario\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91761-7762\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 4, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #728227\u003C\u002Fp>\u003Cp>Dear Mr. Savalia:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1845 S. Vineyard Ave, Ste 5, Ontario, CA, from March 16-27, 2026. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on March 27, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 14 and 17, 2026, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from March 16-27, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to ensure that each person who is identified to perform quality control operations is qualified to do so, as required by 21 CFR 111.12(b). Specifically, neither your Operations Manager nor your Production Manager, who are performing the responsibilities of quality control, is qualified to do so, as neither is knowledgeable about the applicable requirements.\u003C\u002Fp>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you identified an employee to lead your quality control unit; however, you provided no information demonstrating that this person is qualified.\u003C\u002Fp>\u003Cp>2. You failed to meet sanitation requirements that apply to your physical plant and grounds, as required by 21 CFR 111.15. Specifically, during the inspection, our investigator observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> pipes \u003Cstrong>(b)(4)\u003C\u002Fstrong> had powder build up and residue different than the color from the product being run in the machines; and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rooms had unknown residue\u002Fbuildup on the floors and walls. Additionally, the corners of your walls in the blending room have holes, and there were temporary patches in place made with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> corners were \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and where \u003Cstrong>(b)(4)\u003C\u002Fstrong> was broken it revealed the damaged wall underneath.\u003C\u002Fli>\u003Cli>You failed to identify and hold cleaning compounds, sanitizing agents, pesticides, pesticide chemicals, or other toxic materials in a manner that protects against contamination of components, dietary supplements, or contact surfaces, as required by 21 CFR 111.15(c)(3). During the walk-through on March 17, 2026, our investigator observed a can of \u003Cstrong>(b)(4)\u003C\u002Fstrong> stored under a table that was adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line. Containers of ingredients, in-process products, and finished products of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were held adjacent or in the same area.\u003C\u002Fli>\u003Cli>You failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). Specifically, we observed a gap at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> tall at the bottom of an exit door in your warehouse, which does not prevent entry by pests.\u003C\u002Fli>\u003Cli>You failed to establish plumbing in your physical plant that is of an adequate size and design and that is adequately installed and maintained to properly convey sewage and liquid disposable waste from your physical plant, as required by 21 CFR 111.15(f)(2). Specifically, your firm is currently not allowed to discharge wastewater and is storing all liquid waste in a container located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room. Adjacent to the enclosed container is an uncovered container with a pump inside filled with liquid of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We noted the uncovered container, and its immediate surroundings, were not maintained in a sanitary manner, with apparent splash marks and other unidentifiable substances on and around containers and along the wall. The wastewater containers were a few feet away from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> ladders.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you were going to ensure that all doors are sealed or fitted with pest-proof sweeps, that you have moved all cleaning agents to a designated location, and that you have moved the containers of liquid waste to a designated area. However, you have not provided any photos or documentation of evidence to confirm corrective action has taken place.\u003C\u002Fp>\u003Cp>3. You failed to establish the following specifications, as required by 21 CFR 111.70:\u003C\u002Fp>\u003Cul>\u003Cli>For components used in the manufacture of a dietary supplement, you did not establish identity specifications; specifications necessary to ensure the specifications for purity, strength, and composition of the dietary supplement are met; and limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). For example, you failed to establish specifications for the identity or limits of contaminates for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture the dietary supplement product \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you failed to establish specifications for the identity or limits of contaminants for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture the dietary supplement product \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>For each dietary supplement that you manufacture, you did not establish product specifications for the identity, purity, strength, and composition of the finished batches of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). You have not established specifications for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you will establish component and dietary supplement specifications; however, you have not submitted any further evidence of this corrective action to date.\u003C\u002Fp>\u003Cp>4. You failed to prepare a batch production record (BPR) every time you manufactured a batch of a dietary supplement, as required by 21 CFR 111.255(a). Specifically, during the inspection you were unable to provide our investigator with a batch production record for your packaging operations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement product, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, for other dietary supplements you failed to prepare a BPR that includes all information required under 21 CFR 111.260. For example, your batch production records for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) dietary supplement products that you manufacture failed to include:\u003C\u002Fp>\u003Cul>\u003Cli>A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\u003C\u002Fli>\u003Cli>Documentation, at the time of performance, of the manufacture of the batch (21 CFR 111.260(j)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you retroactively created a BPR for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and placed lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on hold pending full quality review and release. For other products you stated that you created new master BPR templates and were planning to implement an \u003Cstrong>(b)(4)\u003C\u002Fstrong> record system in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you have not provided any evidence of these corrective actions.\u003C\u002Fp>\u003Cp>5. You failed to take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements by failing to use effective measures to protect against the inclusion of metal or other foreign material in components or dietary supplements, as required by 21 CFR 111.365(i). Specifically, on March 16, 2026, your metal detector was not properly connected while filling and packaging a dietary supplement product. On March 17, 2026, our investigator observed the metal detector check failing to detect the metal test pieces. On March 23, 2026, our investigator observed that the employee using the metal detector was not performing the metal detector check properly and was not documenting the actual time of performance.\u003C\u002Fp>\u003Cp>We have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you have recalibrated your metal detector. Calibrating your metal detector will not address the root causes of this violation in full.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #728227 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Vishal D. Savalia\n\nRecipient Title\n\nChief Operating Officer\n\nAmerican Pharma Mfg. Inc.\n\n1845 S. Vineyard Ave Ste 5\n\nOntario, CA 91761-7762\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nAugust 4, 2026\nWARNING LETTER\nCMS #728227\nDear Mr. Savalia:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1845 S. Vineyard Ave, Ste 5, Ontario, CA, from March 16-27, 2026. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on March 27, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 14 and 17, 2026, and we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from March 16-27, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to ensure that each person who is identified to perform quality control operations is qualified to do so, as required by 21 CFR 111.12(b). Specifically, neither your Operations Manager nor your Production Manager, who are performing the responsibilities of quality control, is qualified to do so, as neither is knowledgeable about the applicable requirements.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you identified an employee to lead your quality control unit; however, you provided no information demonstrating that this person is qualified.\n2. You failed to meet sanitation requirements that apply to your physical plant and grounds, as required by 21 CFR 111.15. Specifically, during the inspection, our investigator observed the following:\nYou failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). Specifically, the (b)(4) pipes (b)(4) had powder build up and residue different than the color from the product being run in the machines; and the (b)(4) rooms had unknown residue\u002Fbuildup on the floors and walls. Additionally, the corners of your walls in the blending room have holes, and there were temporary patches in place made with (b)(4) and (b)(4). At least (b)(4) corners were (b)(4), and where (b)(4) was broken it revealed the damaged wall underneath.\nYou failed to identify and hold cleaning compounds, sanitizing agents, pesticides, pesticide chemicals, or other toxic materials in a manner that protects against contamination of components, dietary supplements, or contact surfaces, as required by 21 CFR 111.15(c)(3). During the walk-through on March 17, 2026, our investigator observed a can of (b)(4) stored under a table that was adjacent to the (b)(4) filling line. Containers of ingredients, in-process products, and finished products of (b)(4), Lot (b)(4), were held adjacent or in the same area.\nYou failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). Specifically, we observed a gap at least (b)(4) tall at the bottom of an exit door in your warehouse, which does not prevent entry by pests.\nYou failed to establish plumbing in your physical plant that is of an adequate size and design and that is adequately installed and maintained to properly convey sewage and liquid disposable waste from your physical plant, as required by 21 CFR 111.15(f)(2). Specifically, your firm is currently not allowed to discharge wastewater and is storing all liquid waste in a container located in the (b)(4) room. Adjacent to the enclosed container is an uncovered container with a pump inside filled with liquid of (b)(4). We noted the uncovered container, and its immediate surroundings, were not maintained in a sanitary manner, with apparent splash marks and other unidentifiable substances on and around containers and along the wall. The wastewater containers were a few feet away from the (b)(4) and (b)(4) ladders.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you were going to ensure that all doors are sealed or fitted with pest-proof sweeps, that you have moved all cleaning agents to a designated location, and that you have moved the containers of liquid waste to a designated area. However, you have not provided any photos or documentation of evidence to confirm corrective action has taken place.\n3. You failed to establish the following specifications, as required by 21 CFR 111.70:\nFor components used in the manufacture of a dietary supplement, you did not establish identity specifications; specifications necessary to ensure the specifications for purity, strength, and composition of the dietary supplement are met; and limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). For example, you failed to establish specifications for the identity or limits of contaminates for the components (b)(4) and (b)(4) used to manufacture the dietary supplement product (b)(4). In addition, you failed to establish specifications for the identity or limits of contaminants for the components (b)(4) and (b)(4) used to manufacture the dietary supplement product (b)(4).\nFor each dietary supplement that you manufacture, you did not establish product specifications for the identity, purity, strength, and composition of the finished batches of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). You have not established specifications for your (b)(4) and (b)(4) dietary supplement products.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you will establish component and dietary supplement specifications; however, you have not submitted any further evidence of this corrective action to date.\n4. You failed to prepare a batch production record (BPR) every time you manufactured a batch of a dietary supplement, as required by 21 CFR 111.255(a). Specifically, during the inspection you were unable to provide our investigator with a batch production record for your packaging operations for your (b)(4) dietary supplement product, lot (b)(4). Additionally, for other dietary supplements you failed to prepare a BPR that includes all information required under 21 CFR 111.260. For example, your batch production records for the (b)(4) (lot (b)(4)) and (b)(4) (lot (b)(4)) dietary supplement products that you manufacture failed to include:\nA statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\nDocumentation, at the time of performance, of the manufacture of the batch (21 CFR 111.260(j)).\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you stated that you retroactively created a BPR for the (b)(4) product and placed lot (b)(4) on hold pending full quality review and release. For other products you stated that you created new master BPR templates and were planning to implement an (b)(4) record system in (b)(4). However, you have not provided any evidence of these corrective actions.\n5. You failed to take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements by failing to use effective measures to protect against the inclusion of metal or other foreign material in components or dietary supplements, as required by 21 CFR 111.365(i). Specifically, on March 16, 2026, your metal detector was not properly connected while filling and packaging a dietary supplement product. On March 17, 2026, our investigator observed the metal detector check failing to detect the metal test pieces. On March 23, 2026, our investigator observed that the employee using the metal detector was not performing the metal detector check properly and was not documenting the actual time of performance.\nWe have reviewed your responses, dated April 14 and 17, 2026. Your responses fail to demonstrate that you have adequately addressed the violation. In your response, you state that you have recalibrated your metal detector. Calibrating your metal detector will not address the root causes of this violation in full.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #728227 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","American Pharma Mfg. Inc.","american-pharma-mfg-inc-728227-08042026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-pharma-mfg-inc-728227-08042026","2026-11-10T01:02:16.121874+00:00","Warning Letter","Issued","2026-09-29","728227","Dietary Supplements","Mr. Vishal D. Savalia","2026-10-14T12:34:14.48+00:00","Via Email","2026-08-04",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2337,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022\">BergaMet North America LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jay Decker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BergaMet North America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6445 S. Tenaya Way Suite B110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89113-1989\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@bergametna.com\"> orders@bergametna.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636315\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay Decker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\u003Cbr>\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-inflammatory”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Reduces cholesterol”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n\u003Cbr>\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;On a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\u003Cbr>\n&nbsp; o “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\u003Cbr>\n&nbsp; o “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\u003Cbr>\n&nbsp; o You also endorsed the following responses to your post by liking them:\u003Cbr>\n&nbsp; &nbsp; 􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Yes!! Mine went down 38 points.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jay Decker\n\nBergaMet North America LLC\n\n6445 S. Tenaya Way Suite B110\n\nLas Vegas, NV 89113-1989\n\nUnited States\n\norders@bergametna.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636315\n\nDear Mr. Jay Decker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\n\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\n\n“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\n\n“Anti-inflammatory”\n\n“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\n\n“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\n\n“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\n\nOn your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\n\n“Reduces cholesterol”\n\n“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\n\nOn your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\n\n“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\n\n“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\n\nOn your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\n\nOn a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\n\no “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\n\no “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\n\no “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\n\no You also endorsed the following responses to your post by liking them:\n\n􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\n\n“Yes!! Mine went down 38 points.”\n\nYour Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","BergaMet North America LLC","bergamet-north-america-llc-636315-11142022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022","2026-10-26T08:08:03.414177+00:00","2022-11-17","636315","Dietary SupplementsDrugs","Mr. Jay Decker","2026-08-20T01:25:33.357+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",2,{"510k":56,"classification":57,"enforcement":58,"event":59,"event_backfill":60,"pma":61,"warning_letter":62},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]